Elevation Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELEV research report →
Range $8 – $10
Price Chart
About the company
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial.
- CEO
- Joseph J. Ferra Jr.
- IPO
- 2021
- Employees
- 34
- HQ
- Boston, NY, US
Get TickerSpark's AI analysis on ELEV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $21.63M
- P/E
- -0.47
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 0.35
- EV/EBITDA
- -0.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -77.48%
- ROIC
- -49.04%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-24,000+38.5%
- Op Income
- $-44,703,000
- Net Income
- $-44,485,000+2.7%
- EPS
- $-0.78+41.8%
- OCF Growth
- +35.3%
- FCF Growth
- +35.3%
- 52W High
- $3.09
- 52W Low
- $0.22
- 50D MA
- $0.35
- 200D MA
- $0.49
- Beta
- 1.50
- RSI (14)
- 46
- Avg Volume
- 1.35M
No earnings-call transcripts are available for ELEV yet.
- Free Float
- 73.4%
- Shares Outstanding
- 59.25M
- Float Shares
- 43.51M
of shares held by institutions
72 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 2.49M | ▲ 2.32M |
| Nuveen Asset Management, LLC | 174.14K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 23, 25 | Sandler Alan B. | sell | 35,000 |
| Jul 23, 25 | Sandler Alan B. | sell | 55,000 |
| Jul 23, 25 | Sandler Alan B. | sell | 35,000 |
| Jul 23, 25 | Mootz Darcy | sell | 55,000 |
| Jul 23, 25 | Mootz Darcy | sell | 35,000 |
| Jul 23, 25 | Mootz Darcy | sell | 35,000 |
| Jul 23, 25 | ELMS STEVE | sell | 35,000 |
| Jul 23, 25 | ELMS STEVE | sell | 35,000 |
| Jul 23, 25 | ELMS STEVE | sell | 31,238 |
| Jul 23, 25 | ELMS STEVE | sell | 15,619 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ELEV coverage
Recent articles, reports, and earnings notes.
No research on ELEV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELEV report →HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)
globenewswire.com · Jun 15
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
prnewswire.com · Jun 12
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV
businesswire.com · Jun 10
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
businesswire.com · Jun 9
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
prnewswire.com · Jun 9
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
prnewswire.com · May 15
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
prnewswire.com · Apr 25
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
prnewswire.com · Mar 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.